How did Edes manage to grow its revenue while controlling expenses in Q4 2024?

Edesa Biotech achieved revenue growth and controlled expenses in Q4 2024 through strategic initiatives and government funding:

1. **Revenue Growth**: Edesa Biotech reported a strong second half performance, marking the biggest second half in the company's history. This was driven by successful strategic acquisitions, which contributed an annualized EBIT of $14 million.
2. **Expense Control**: The company reduced its operating expenses by over 20%, resulting in a net loss of $6.2 million for the year, down from $8.4 million the previous year. This was achieved through planned initiatives to reduce operating expenses across all cost groups, including significant declines in employee-related expenses, occupancy expense, and stock compensation expense.